Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

Ahmad M. Mansour, Friederike Mackensen, J. Fernando Arevalo, Focke Ziemssen, Padmamalini Mahendradas, Abla Mehio-Sibai, Nicholas Hrisomalos, Timothy Y.Y. Lai, David Dodwell, Wai Man Chan, Thomas Ness, Alay S. Banker, Sivakami A. Pai, Maria H. Berrocal, Rania Tohme, Arnd Heiligenhaus, Ziad F. Bashshur, Moncef Khairallah, Khalil M. Salem, Frank N. HrisomalosMatthew H. Wood, Wilson Heriot, Alfredo Adan, Atul Kumar, Lyndell Lim, Anthony Hall, Matthias Becker

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the role of bevacizumab in inflammatory ocular neovascularization. Design: Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization. Methods: Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best-corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up. Results: At the three-month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and 11 eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6/28 or 20/94) to 0.44 (6/17 or 20/55) (P < .001). BCVA improved by one to three lines in 34.5% of the eyes, by four to six lines in 16.7% of the eyes, and by more than six lines in 14.2% of the eyes. Function was unchanged in 23.8% of the eyes. BCVA worsened in 10.7% (zero to three lines in 7.1%, more than four lines in 3.6%). Central foveal thickness decreased from baseline 346 to 252 μm (P < .001). For CNV, 32 eyes (43.2%) had complete regression after the injection, 27 (36.5%) had partial regression, five (6.8%) had no response, and 10 eyes (13.5%) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6%) had complete regression of new vessels and four eyes (36.4%) had partial regression after the injection. Conclusions: Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases.

Original languageEnglish (US)
Pages (from-to)410-416.e1
JournalAmerican journal of ophthalmology
Volume146
Issue number3
DOIs
StatePublished - Sep 2008

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Mansour, A. M., Mackensen, F., Arevalo, J. F., Ziemssen, F., Mahendradas, P., Mehio-Sibai, A., Hrisomalos, N., Lai, T. Y. Y., Dodwell, D., Chan, W. M., Ness, T., Banker, A. S., Pai, S. A., Berrocal, M. H., Tohme, R., Heiligenhaus, A., Bashshur, Z. F., Khairallah, M., Salem, K. M., ... Becker, M. (2008). Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization. American journal of ophthalmology, 146(3), 410-416.e1. https://doi.org/10.1016/j.ajo.2008.05.024